December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2009-010198-19/ Novartis Protocol ID CLCQ908A2204

A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidemia.

Trial CLCQ908A2204 was cancelled with no patient enrollment and as such, no results will be reported.